Additional Target Proteins Sample Clauses

Additional Target Proteins. In the event that Proof of Principle is achieved (either (a) or (b) as defined in Section 1.25) and Lilly has received the Final Comprehensive Report for the last Initial Target Protein within at least nintey (90) days after the expiration of the timeline set forth in the last sentence of Section 2.1 of this Agreement (provided that such period shall be extended to the extent that any delay beyond such period was caused by Lilly), Lilly and Scriptgen hereby agree to expand the Project to include two (2) additional Target Proteins for ATLAS Screening (the "Additional Target Proteins") under exactly the same terms as are applicable to the Initial Target Proteins under this Agreement except that: (a) the Research Fee described in Section 3.1 shall be [***] for both of the Additional Target Proteins as opposed to the [***] Research Fee that applies to the Initial Target Proteins; (b) the first installment payment of such Research Fee under Section 3.2 hereof, for the Additional Target Proteins shall be paid within [***] as opposed to thirty (30) days after the execution of this Agreement; (c) the original terms set forth in Section 1.22, 1.23 and 2.1 of the Agreement shall continue to be applicable with respect to the Additional Target Proteins as opposed to the amended versions of Section 1.22, 1.23 and 2.1 as described in this Amendment unless Lilly elects, at its sole discretion, to exercise its Additional Compound Option (as defined below in this Section 2.6); and (d) Section 3.4 of this Amendment shall not be applicable with respect to the Additional Target Proteins unless Lilly elects, at its sole discretion, to exercise its Additional Compound Option (as defined below in this Section 2.6) For avoidance of any doubt the second installment payment of the Research Fee shall be paid within [***] with respect to the Additional Target Proteins. Xx. Xxxxx Xxxxxx October 8, 1997 Page 5 Lilly may, at its sole discretion, elect to increase the compounds screened against the Additional Target Proteins pursuant to the same terms that apply to the Initial Target Proteins as described in Sections 1.22, 1.23, 2.1 and 3.4 of this Amendment except that the first payment installment under Section 3.4 with respect to the Additional Target Proteins shall be within ten (10) days of Lilly exercising the Additional Compound Option as opposed to ten (10) days within execution of this Amendment ("Additional Compound Option"). In order for Lilly to elect to exercise its Addition...
Sample 1Sample 2
AutoNDA by SimpleDocs
Additional Target Proteins. In the event that Proof of Principle is achieved (either (a) or (b) as defined in Section 1.25) and Lilly has received the Final Comprehensive Report for the last Initial Target Protein within at least ninety (90) days after the expiration of the timeline set forth in the last sentence of Section 2.1 of this Agreement (provided that such period shall be extended to the extent that any delay beyond such period was caused by Lilly), Lilly and Scriptgen hereby agree to expand the Project to include two (2) additional Target Proteins for ATLAS Screening (the "Additional Target Proteins") under exactly the same terms as are applicable to the Target Proteins under this Agreement except that: (a) the Research Fee described in Section 3.1 shall be [***] for both of the Additional Target Proteins as opposed to the [***] Research Fee that applies to the Initial Target Proteins; and (b) the first installment payment of such Research Fee under Section 3.2 hereof, for the Additional Target Proteins shall be paid within thirty (30) days of Lilly's receipt of the Final Comprehensive Report for the last Initial Target Protein as opposed to thirty (30) days after the execution of this Agreement. For avoidance of any doubt the second installment payment of the Research Fee shall be paid within thirty (30) days after Lilly's receipt of the Final Comprehensive Report with respect to the Additional Target Proteins.
Sample 1Sample 2

Related to Additional Target Proteins

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Targets Seller’s supplier diversity spending target for Work supporting the construction of the Project prior to the Commercial Operation Date is ____ percent (___%) as measured relative to Seller’s total expenditures on construction of the Project prior to the Commercial Operation Date, and;

  • Multi-year Planning Targets Schedule A may reflect an allocation for the first Funding Year of this Agreement as well as planning targets for up to two additional years, consistent with the term of this Agreement. In such an event, the HSP acknowledges that if it is provided with planning targets, these targets: a. are targets only, b. are provided solely for the purposes of planning, c. are subject to confirmation, and d. may be changed at the discretion of the Funder in consultation with the HSP. The HSP will proactively manage the risks associated with multi-year planning and the potential changes to the planning targets; and the Funder agrees that it will communicate any changes to the planning targets as soon as reasonably possible.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Development Schedule The Project shall substantially comply with the specific timetables and triggers for action set forth in Article 5 of this Agreement. The parties acknowledge that, as provided in G.S. 160A-400.25(b), the failure to meet a commencement or completion date shall not, in and of itself, constitute a material breach of this Agreement pursuant to G.S. 160A-400.27 but must be judged based upon the totality of the circumstances.

  • Project Specific Milestones In addition to the milestones stated in Section 212.5 of the Tariff, as applicable, during the term of this ISA, Interconnection Customer shall ensure that it meets each of the following development milestones: 6.1 Substantial Site work completed. On or before December 31, 2020 Interconnection Customer must demonstrate completion of at least 20% of project site construction. At this time, Interconnection Customer must submit to Interconnected Transmission Owner and Transmission Provider initial drawings, certified by a professional engineer, of the Customer Interconnection Facilities. 6.2 Delivery of major electrical equipment. On or before December 31, 2021, Interconnection Customer must demonstrate that all generating units have been delivered to Interconnection Customer’s project site.

  • Acceptance Criteria The Services and Deliverables must meet the following acceptance criteria or the JBE may reject the applicable Services or Deliverables. The JBE may use the attached Acceptance and Signoff Form to notify Contractor of the acceptance or rejection of the Services and Deliverables. Contractor will not be paid for any rejected Services or Deliverables.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Evaluation Criteria 5.2.1. The responses will be evaluated based on the following: (edit evaluation criteria below as appropriate for your project)

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!